What is Zacks Research's Forecast for PCRX FY2027 Earnings?

Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Equities research analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for Pacira BioSciences in a research report issued to clients and investors on Thursday, March 20th. Zacks Research analyst R. Department forecasts that the company will post earnings per share of $2.45 for the year. The consensus estimate for Pacira BioSciences' current full-year earnings is $2.41 per share.

A number of other brokerages have also issued reports on PCRX. Royal Bank of Canada restated a "sector perform" rating and set a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Barclays lifted their target price on Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. HC Wainwright raised their price target on shares of Pacira BioSciences from $57.00 to $70.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Needham & Company LLC upped their price objective on shares of Pacira BioSciences from $30.00 to $32.00 and gave the company a "buy" rating in a report on Friday, February 28th. Finally, Truist Financial raised Pacira BioSciences from a "sell" rating to a "hold" rating and increased their price target for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Pacira BioSciences presently has a consensus rating of "Hold" and a consensus target price of $27.22.

Remove Ads

Pacira BioSciences Stock Performance

Shares of Pacira BioSciences stock traded up $0.88 during midday trading on Monday, hitting $25.30. The company had a trading volume of 803,782 shares, compared to its average volume of 873,860. The company has a fifty day simple moving average of $24.65 and a 200 day simple moving average of $19.79. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -12.46 and a beta of 0.86. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. Pacira BioSciences has a 12-month low of $11.16 and a 12-month high of $31.67.

Institutional Trading of Pacira BioSciences

Institutional investors have recently modified their holdings of the stock. State Street Corp boosted its holdings in Pacira BioSciences by 5.8% in the 3rd quarter. State Street Corp now owns 2,014,012 shares of the company's stock worth $30,311,000 after buying an additional 110,162 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Pacira BioSciences by 0.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,992,601 shares of the company's stock worth $37,541,000 after acquiring an additional 13,604 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Pacira BioSciences by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,091,970 shares of the company's stock worth $20,578,000 after purchasing an additional 5,071 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Pacira BioSciences in the 4th quarter valued at $20,266,000. Finally, Nuveen Asset Management LLC lifted its holdings in Pacira BioSciences by 109.9% in the 4th quarter. Nuveen Asset Management LLC now owns 625,917 shares of the company's stock valued at $11,792,000 after purchasing an additional 327,754 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company's stock.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.